Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 4/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717559 | 0.96 | POLB (0.52) | POLBGPR142CCR2ESR1ESR2 | |
| SCHEMBL31566056 | 0.86 | POLB (0.56) | POLBCCR2CNR1CNR2NAMPT | |
| SCHEMBL31566060 | 0.82 | POLB (0.49) | POLBCCR2ESR1ESR2 | |
| SCHEMBL13718336 | 0.80 | ESR1 (0.52) | GPR142CCR2ESR1ESR2 | |
| SCHEMBL13717278 | 0.79 | ESR1 (0.49) | GPR142CCR2ESR1ESR2 | |
| SCHEMBL13717597 | 0.79 | ESR1 (0.49) | GPR142CCR2ESR1ESR2 | |
| SCHEMBL13717782 | 0.79 | RAB9A (0.62) | GPR142TRPV1NAMPTALDH1A1LMNA | |
| SCHEMBL13718177 | 0.78 | ESR1 (0.45) | GPR142CCR2ESR1ESR2 | |
| SCHEMBL13718240 | 0.78 | ESR1 (0.45) | GPR142CCR2ESR1ESR2 | |
| SCHEMBL19808771 | 0.78 | ESR1 (0.45) | GPR142CCR2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | claimed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| EP-2707361-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | claimed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20140329755-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | GILEAD SCIENCES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014179492-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | GILEAD SCIENCES, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2707361-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | POLB 4763/4885GPR142 1139/4885CCR2 2899/4885 |
| US-20140329755-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | CAMKK2, CAMK4, CAMK1 | POLB 3771/4885GPR142 3369/4885CCR2 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.